Ezetimibe, sold as Zetia, is an inexpensive daily pill that lowers LDL cholesterol and apoB by blocking a transporter that absorbs cholesterol in the small intestine. It works differently from statins, so the two add up. On its own it lowers LDL by about 18%, and about another 20% when added to a statin. In the IMPROVE-IT trial, adding ezetimibe to a statin after a heart attack modestly lowered the risk of further heart attacks and strokes, though it did not reduce the risk of dying. It is well tolerated, without the muscle symptoms statins can cause, and it is the standard first add-on when a statin alone does not reach the target.
TL;DR: Ezetimibe, sold as Zetia, is a cheap, generic, once-daily pill that lowers LDL cholesterol and apoB by blocking the gut transporter (NPC1L1) that absorbs cholesterol. Because statins lower cholesterol production while ezetimibe lowers cholesterol absorption, the two work on different pathways and add up. Alone it drops LDL by about 18%; added to a statin it removes about another 20%. In the large IMPROVE-IT trial, adding ezetimibe to a statin after a heart attack modestly lowered the rate of further heart attacks and strokes, the first proof that a non-statin drug added on top of a statin reduces events. Its benefit is meaningful but modest, and it did not lower the risk of death. It is close to placebo for side effects, with none of the muscle symptoms statins can cause, which makes it the standard first add-on when a statin alone does not reach the target, and a useful option for people who cannot take a full statin dose.
What is ezetimibe, and how does it work?
Ezetimibe, sold under the brand name Zetia, is a once-daily pill that lowers cholesterol by a route no other common drug uses. It blocks a transporter called NPC1L1 that sits on the cells lining the small intestine and pulls cholesterol into the body. That cholesterol comes both from food and from bile the liver releases into the gut, so blocking its uptake lowers the amount of cholesterol reaching the bloodstream. The liver responds by pulling more LDL out of the blood, and the LDL level falls.
The pairing works because ezetimibe uses a different mechanism from statins. Statins lower how much cholesterol the liver makes; ezetimibe lowers how much the gut absorbs. Two different levers on the same system means the effects add together, which is why ezetimibe is most often used alongside a statin rather than by itself.
How much does ezetimibe lower cholesterol?
On its own, ezetimibe lowers LDL cholesterol by about 18%. Added on top of a statin, it removes roughly another 20%, which is more lowering than you would usually gain by stepping the statin dose up one or two levels. It lowers apoB, the count of cholesterol-carrying particles that many physicians now treat as the truer target, roughly in line with its effect on LDL. Our apoB guide explains why that particle count matters more than the standard cholesterol number.
The size of the drop is moderate, so ezetimibe is rarely the whole answer for someone who needs their LDL cut in half. It is a steady contributor that helps close the gap between a good statin result and an aggressive target.
Does ezetimibe prevent heart attacks?
For years this was the open question, because lowering a lab number is not the same as preventing an event. The answer came from IMPROVE-IT, a trial of more than 18,000 people who had recently had a heart attack or unstable angina. Everyone took a statin; half also took ezetimibe. Over about 7 years, the group on ezetimibe reached a lower LDL, about 54 versus 70 mg/dL, and had modestly fewer cardiovascular events, 32.7% versus 34.7%.1
That gap is about 2 percentage points, a modest but genuine benefit, and it carried weight beyond its size. IMPROVE-IT was the first trial to show that adding a non-statin cholesterol drug on top of a statin lowers cardiovascular risk further, which supported the broader idea that what matters is how low the LDL and apoB go, rather than which drug gets you there. The benefit came from fewer heart attacks and ischemic strokes. It did not lower the risk of cardiovascular death or death from any cause, so ezetimibe should be understood as a drug that reduces nonfatal events in proportion to how much extra LDL it removes and how high the person's risk was to begin with.
Why was there doubt about ezetimibe for so long?
Part of the reason is a trial called ENHANCE. In 2008, it tested ezetimibe plus a statin against the statin alone in people with an inherited cholesterol disorder, measuring the thickness of the carotid artery wall as a stand-in for progress. Despite a lower LDL, the ezetimibe group showed no improvement in that measurement.2 The result cast doubt on whether ezetimibe's LDL lowering translated into anything meaningful.
The lesson turned out to be about the limits of surrogate measurements. Artery-wall thickness is an indirect marker, and it did not capture the benefit that a hard-outcome trial later found. When IMPROVE-IT measured heart attacks and strokes directly, the benefit appeared. It is a good reminder that the endpoint that counts is the event you are trying to prevent, and that a drug can look disappointing on an imaging test and still help.
How is ezetimibe combined with other drugs?
Ezetimibe is a team player, and most of its value shows up in combination.
The most common pairing is with a statin, either as two pills or as a single combination pill, sold as Vytorin with simvastatin. For people who cannot tolerate a full statin dose, a lower or alternate-day statin plus ezetimibe can reach the same target with fewer side effects. The RACING trial tested this idea directly: a moderate statin dose plus ezetimibe worked as well as a high statin dose alone for preventing events, with fewer people stopping the drug for side effects.3 That trial was designed to show equivalence rather than superiority, so the takeaway is that the combination is a well-tolerated way to reach the goal, rather than a sign that it beats a strong statin.
Ezetimibe is also paired with bempedoic acid in a combination pill sold as Nexlizet, an all-oral option for people who cannot take statins at all. And it is often part of the layered plan described in beyond statins, where the goal is to reach the apoB target with whatever combination the person tolerates.
Who is ezetimibe for?
Ezetimibe fits several situations. The clearest is a person already on the highest statin dose they tolerate whose LDL or apoB is still above target; ezetimibe is the standard first drug to add, endorsed in that role by major cardiology guidelines because it is proven, cheap, and easy. It also suits people who get muscle symptoms on statins and need a well-tolerated way to lower cholesterol, whether combined with a small statin dose or with bempedoic acid.
Its strongest evidence is in people who already have heart disease or are at high risk, which is where IMPROVE-IT and RACING were run. In lower-risk prevention, it is used mainly for people with very high inherited cholesterol or those who cannot take statins, where the hard-outcome evidence is thinner. As with any cholesterol drug, the decision rests on your absolute risk and your numbers, since the size of the benefit tracks how high your risk is to start.
Guidance from the Clinic
Key Takeaways
- Ezetimibe (Zetia) is a cheap, generic, once-daily pill that lowers LDL and apoB by blocking cholesterol absorption in the gut, a different mechanism from statins.
- It lowers LDL by about 18% alone and roughly another 20% when added to a statin, and it lowers apoB in step.
- In the IMPROVE-IT trial, adding ezetimibe to a statin after a heart attack modestly reduced heart attacks and ischemic strokes, the first proof that a non-statin drug added to a statin lowers events, though it did not reduce deaths.
- It is close to placebo for side effects, with none of the statin muscle symptoms, which makes it the standard first add-on and a useful option for the statin-intolerant, including the combination pills Vytorin and Nexlizet.
- Its benefit is modest and scales with your baseline risk, so it helps most in people who already have heart disease or very high cholesterol.
Related at Fishtown Medicine
- Beyond Statins: Lowering Cholesterol - the full menu of options when statins are not enough
- ApoB and Heart Health - the particle count ezetimibe lowers, and why it matters
- Bempedoic Acid (Nexletol) - the statin-free partner in the Nexlizet combination pill
- Inclisiran (Leqvio) - the twice-yearly injection for when more lowering is needed
- PCSK9 Inhibitors (Repatha, Praluent) - the strongest LDL-lowering class when more is needed
- What Is a Preventive Cardiologist? - how these drug choices get made
Scientific References
- Cannon CP, Blazing MA, Giugliano RP, et al. "Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes." New England Journal of Medicine. 2015;372(25):2387-2397.
- Kastelein JJP, Akdim F, Stroes ESG, et al. "Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia." New England Journal of Medicine. 2008;358(14):1431-1443.
- Kim BK, Hong SJ, Lee YJ, et al. "Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial." Lancet. 2022;400(10349):380-390.
Frequently Asked Questions
Common Questions
Deep-Dive Questions
Ready when you are
Dr. Ash reads every intake himself, and answers questions personally - usually within a few hours.
